This third edition of this well-received text continues to provide a state-of-the-art treatise on modern clinical practice relating to hyperlipidemia and lipoprotein disorders, conditions responsible for a huge amount of morbidity and mortality in Western countries and, increasingly, the developing world. The clinical evidence underlying the treatment of hyperlipidemia has burgeoned since the second edition published in 1994, with the publication of the results of many clinical trials on the new statin drugs, and teh ...
Read More
This third edition of this well-received text continues to provide a state-of-the-art treatise on modern clinical practice relating to hyperlipidemia and lipoprotein disorders, conditions responsible for a huge amount of morbidity and mortality in Western countries and, increasingly, the developing world. The clinical evidence underlying the treatment of hyperlipidemia has burgeoned since the second edition published in 1994, with the publication of the results of many clinical trials on the new statin drugs, and teh subsequent appearance of national and international guidelines for cholesterol lowering in coronary prevention. There has also been considerable development in the definition of cardiovascular risk, and the methodology for identifying high-risk patients. All of these aspects are addressed fully in the new edition. In addition, the book offers helpful summaries of the background biochemistry of lipoprotein metabolism and atherosclerosis where relevant, putting the subject in the context of its pathophysiology and epidemiology. The text relating to clinical aspects has a strong evidence base, reviewing, in particular, areas of uncertainty and controversy. Drawing on the wealth of experience of the author, and representing his widely respected views on the subject, readers will find this comprehensive, well-referenced and accessible book invaluable.
Read Less
